NHRA Logo - Orginal 250.png
CASGEVY Gets Bahrain approval for treatment, marking it second country in the world
December 02, 2023 12:59 ET | National Health Regulatory Authority
CASGEVY Gets Bahrain approval for treatment, marking it second country in the world
AB Science tiendra u
AB Science tiendra une conférence virtuelle le jeudi 30 novembre 2023, de 15h à 16h, pour présenter le programme de développement clinique du masitinib dans la drépanocytose.
November 28, 2023 13:22 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR LE JEUDI 30 NOVEMBRE 2023, DE 15H A 16H, SUR LE PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA DREPANOCYTOSE Paris, 28...
AB Science will host
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
November 28, 2023 13:22 ET | AB Science
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, 28 november, 2023, 7.15pm CET ...
AB Science : Le déve
AB Science : Le développement clinique du masitinib dans la drépanocytose fait partie des 19 projets lauréats dans le cadre du 6eme appel à projet RHU
November 27, 2023 02:04 ET | AB Science
COMMUNIQUE DE PRESSE LE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA DREPANOCYTOSE, UNE MALADIE GENETIQUE TRES REPANDUE, FAIT PARTIE DES 19 PROJETS LAUREATS DANS LE CADRE DU SIXIEME APPEL A PROJETS...
AB Science: The clin
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
November 27, 2023 02:04 ET | AB Science
PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY...
TIP_link_300x300.jpg
Malaria and Sickle Cell Disease Treatment Market Worth $29.17 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
November 03, 2023 08:33 ET | The Insight Partners
Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...
OPEN SANS HH STACKED_2.jpg
California State Treasurer, Fiona Ma, and US-India cross-border association, AllianceIndus, congratulate Hemex Health for India partnerships that led to a breakthrough test for sickle cell disease
October 17, 2023 21:00 ET | Hemex Health
SAN FRANCISCO and PORTLAND, Ore., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemex Health, Inc., a medical device company based in Portland, Oregon and Mumbai, India, was honored today by AllianceIndus at...
Sickle Cell Disease Treatment Market
Sickle Cell Disease Treatment Market Size to Surpass USD 9.84 Billion by 2030, exhibiting a CAGR of 20.1%
October 16, 2023 06:42 ET | Fortune Business Insights
Pune, India, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Global Sickle Cell Disease Treatment Market Size was valued at USD 2.25 billion in 2022 and is projected to USD 9.84 billion by 2030 exhibiting a CAGR...
Sickle Cell Disease Treatment Market Globenewswire
Sickle Cell Disease Treatment Market Size to Surpass USD 8.75 Billion by 2029, exhibiting a CAGR of 21.4%
October 05, 2023 04:46 ET | Fortune Business Insights
Pune, India, Oct. 05, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the global Sickle Cell Disease Treatment Market Size was valued at USD 1.73 billion in 2021 and is projected to...
NMDP-BTM_Dual_2_Color_BlueGreen_Logo_RGB_2000x542 (1).png
Sickle Cell Warrior Program from The National Marrow Donor Program® (NMDP)/Be The Match® Expands Access to Bone Marrow Transplant as a Curative Treatment
August 31, 2023 09:00 ET | Be The Match
During Sickle Cell Awareness Month, NMPD/Be The Match reminds individuals to visit SickleCellConnect.com to access essential resources, learn more about Sickle Cell Disease, and join the Be The Match...